Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neramexane - Merz Pharma

Drug Profile

Neramexane - Merz Pharma

Alternative Names: KRP-209; MRZ 2/579; Neramexane mesylate

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merz Pharma
  • Developer Forest Laboratories; Kyorin Pharmaceutical; Merz Pharma
  • Class Amines; Analgesics; Antidementias; Cyclohexanes; Drug withdrawal therapies; Eye disorder therapies; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Alzheimer's disease; Pain; Pathologic nystagmus; Tinnitus

Most Recent Events

  • 09 Jul 2019 Discontinued - Phase-III for Tinnitus in USA, South Africa, Brazil, Mexico, Spain, Portugal, United Kingdom, Belgium, France, Austria, Poland, Netherlands, Netherlands, Czech Republic, Germany (PO) (Merz Pharma website, July 2019)
  • 14 May 2019 Discontinued - Phase-II for Tinnitus in Japan (PO)
  • 06 Nov 2017 Kyorin Pharmaceutical completes a phase II trial for Tinnitus in Japan (PO) (JapicCTI-152984)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top